IL-2 is pivotal in immunotherapy by stimulating T-cell proliferation and activation, enhancing immune responses against cancer cells. Treatment with β-CT-ZnO NPs significantly suppressed IL-2 expression in a dose-dependent manner. The gene discussed is PCYT1B; the disease is cancer.